Literature DB >> 11353628

Resistance studies with daptomycin.

J A Silverman1, N Oliver, T Andrew, T Li.   

Abstract

We studied the in vitro emergence of resistance to daptomycin using three methods: spontaneous resistance incidence, serial passage in the presence of increasing drug concentrations, and chemical mutagenesis. No spontaneously resistant mutants were obtained for any organism tested (<10(-10) for Staphylococcus aureus, <10(-9) for Staphylococcus epidermidis, <10(-9) for Enterococcus faecalis, <10(-9) for Enterococcus faecium, <10(-8) for Streptococcus pneumoniae). Population analysis demonstrated that bacterial susceptibility to daptomycin is heterogeneous. Assay results were sensitive to calcium concentration and culture density, both of which can affect apparent resistance rates. Stable S. aureus mutants were isolated by both serial passage in liquid media and chemical mutagenesis. The daptomycin MICs for these isolates were 8- to 32-fold higher than for the parental strain. Many mutants with high MICs (>12.5 microg/ml) had significant growth defects but did not display phenotypes typical of S. aureus small colony variants. The voltage component (Delta psi) of the bacterial membrane potential was increased in three independent resistant isolates. In vivo data showed that some daptomycin-resistant mutants had lost significant virulence. For other mutants, the degree of in vitro resistance was greater than the change in in vivo susceptibility. These results suggest that infection with some daptomycin-resistant organisms may still be easily treatable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353628      PMCID: PMC90548          DOI: 10.1128/AAC.45.6.1799-1802.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity.

Authors:  D A Steinberg; M A Hurst; C A Fujii; A H Kung; J F Ho; F C Cheng; D J Loury; J C Fiddes
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  [Demonstration of an inoculum effect on the estimation of the minimal inhibitory concentration of LY 146032].

Authors:  J P Flandrois; G Carret; C Pichat; M Peyret
Journal:  Pathol Biol (Paris)       Date:  1988-05

3.  The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis.

Authors:  M Boaretti; P Canepari; M M Lleò; G Satta
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

4.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 5.  Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

6.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae.

Authors:  M Boaretti; P Canepari
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

9.  Proton motive force during growth of Streptococcus lactis cells.

Authors:  E R Kashket; A G Blanchard; W C Metzger
Journal:  J Bacteriol       Date:  1980-07       Impact factor: 3.490

10.  Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; V N Reddy; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

View more
  77 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Population pharmacokinetics of daptomycin.

Authors:  Barry Dvorchik; Robert D Arbeit; Julia Chung; Susan Liu; William Knebel; Helen Kastrissios
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 4.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

5.  In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.

Authors:  Bram M W Diederen; Inge van Duijn; Piet Willemse; Jan A J W Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Impact of daptomycin resistance on Staphylococcus aureus virulence.

Authors:  David R Cameron; Lawrence I Mortin; Aileen Rubio; Eleftherios Mylonakis; Robert C Moellering; George M Eliopoulos; Anton Y Peleg
Journal:  Virulence       Date:  2015       Impact factor: 5.882

7.  Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

Authors:  James H Jorgensen; Sharon A Crawford
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

8.  De novo daptomycin nonsusceptibility in a clinical isolate.

Authors:  Emil P Lesho; Glenn W Wortmann; David Craft; Kimberly A Moran
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

9.  Bactericidal activity and resistance development profiling of dalbavancin.

Authors:  Beth P Goldstein; Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

10.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.